Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2021-01-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
2021年第一次临时股东大会之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening and procedures of the 2021 first extraordinary general meeting (临时股东大会) of 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It details the legality of the meeting's notice, attendance, voting procedures, and resolutions passed. The document does not contain financial statements or results but focuses on the legal compliance and validity of the shareholder meeting and its resolutions. It is not a report of the meeting itself, nor a proxy statement or voting results announcement, but a legal opinion supporting the meeting's procedural correctness. Given the nature of the document as a legal opinion letter related to a shareholder meeting, it best fits under Regulatory Filings (RNS), which is the fallback category for legal and compliance documents that do not fit other specific categories.
2021-01-19 Chinese
关于变更监事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding a change in the company's supervisory board (监事), specifically about the resignation of a supervisor and the election of a new one. It does not contain financial data, audit information, or detailed reports. It is clearly about management/board changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on personnel changes, confirming this classification.
2021-01-19 Chinese
2021年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as the "2021 First Extraordinary General Meeting Resolution Announcement" of the company 福安药业 (Fuan Pharmaceutical). It details the convening of a shareholders' meeting, attendance, voting procedures, and the voting results on specific proposals, including the election of a supervisor and adjustment of subsidiary performance commitments. It also includes legal opinions confirming the legality and validity of the meeting and resolutions. The document is an official announcement of the voting results from a shareholders' meeting, not the meeting materials or the meeting itself. The length is relatively short (2182 characters), and the content focuses on the voting outcomes rather than detailed financial or management reports. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-01-19 Chinese
关于公司产品在国家医保目录中调整情况的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding adjustments to the national medical insurance drug catalog affecting the company's products. It includes details about products newly included and excluded from the catalog and discusses the potential impact on the company's operations. The document is short (840 characters) and is an announcement of regulatory or operational changes rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance information. It is a regulatory announcement about product listing changes relevant to the company's business environment. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-12-30 Chinese
关于召开2021年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2021 first extraordinary general meeting of shareholders for the company 福安药业（集团）股份有限公司. It includes information about the meeting date, agenda items, voting procedures, registration details, and proxy forms. There is no financial data or report content, but rather an announcement and instructions related to the shareholder meeting. The document length is 4138 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), as it provides materials sent to shareholders to inform and request votes for the meeting.
2020-12-28 Chinese
关于调整控股子公司业绩承诺公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the adjustment of performance commitments related to a controlling subsidiary. It details changes in profit commitments due to delays caused by the COVID-19 pandemic and adjustments to the timeline and terms of the agreement. The document includes references to board and supervisory committee approvals and independent director opinions. It is not a full financial report, audit, or earnings release, but rather a regulatory announcement about changes in subsidiary performance commitments and related agreements. The document length is under 5,000 characters and it is an announcement of an adjustment rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-12-28 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.